News | January 21, 2026
Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Over 8.8?million Indians aged 60 and above currently live with dementia,
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Subscribe To Our Newsletter & Stay Updated
